Page 1,811«..1020..1,8101,8111,8121,813..1,8201,830..»

Testimonial John Edwards – Video

Posted: April 2, 2015 at 4:42 pm


Testimonial John Edwards
John Edwards of Roatan provides a testimonial for his orthopedic stem cell treatments recently at GARM.

By: Global Alliance for Regenerative Medicine, Roatan, Honduras

Read the original:
Testimonial John Edwards - Video

Posted in Stem Cell Treatments | Comments Off on Testimonial John Edwards – Video

Stem Cell Connectivity {Duke University Research} – Video

Posted: April 2, 2015 at 4:42 pm


Stem Cell Connectivity {Duke University Research}
A Duke University team has discovered how stem cells build long, slender structures that may ferry signals from one place to another, connecting the stem cell to the critical information it...

By: Duke University

The rest is here:
Stem Cell Connectivity {Duke University Research} - Video

Posted in Stem Cell Research | Comments Off on Stem Cell Connectivity {Duke University Research} – Video

Stem cells age-discriminate organelles to maintain stemness

Posted: April 2, 2015 at 3:53 pm

IMAGE:Human mammary stem-like cell apportions aged mitochondria asymmetrically between daughter cells. Mitochondria were labeled age-selectively red 51 hours prior to imaging, leaving mitochondria that are younger unlabelled. The daughter cell... view more

Credit: Julia Dhla

Tissue stem cells, that continuously renew our tissues, can divide asymmetrically to produce two types of daughter cells. One will be the new stem cell, where as the other will give rise to the differentiating cells of the tissue.

A study jointly lead by laboratories in the Institute of Biotechnology and Massachusetts Institute of Technology (MIT) investigated whether stem cells may also use asymmetric cell division to reduce accumulation of cellular damage. Damage buildup can cause stem cell exhaustion that results in reduced tissue renewal and aging.

Researchers developed a novel approach to follow cellular components, such as organelles, age-selectively during cell division.

"We found that stem cells segregate their old mitochondria to the daughter cell that will differentiate, whereas the new stem cell will receive only young mitochondria" says Pekka Katajisto, a Group leader and Academy research fellow at BI.

Mitochondria appear to be particularly important for stem cells, as other analyzed organelles were not similarly age-discriminated, and since inhibition of normal mitochondrial quality control pathways stopped their age-selective segregation.

"There is a fitness advantage to renewing your mitochondria," says David Sabatini, Professor at MIT and Whitehead Institute. "Stem cells know this and have figured out a way to discard their older components."

While the mechanism used by stem cells to recognize the age of their mitochondria remains unknown, forced symmetric apportioning of aged mitochondria resulted in loss of stemness in all of the daughter cells. "This suggests that the age-selective apportioning of old and potentially damaged organelles may be a way to fight stem cell exhaustion and aging," says Katajisto.

Katajisto laboratory is now exploring how old mitochondria differ from old, and whether this phenomenon occurs in other cell types beyond the human mammary stem-like cells examined here as well as in in vivo.

Read more here:
Stem cells age-discriminate organelles to maintain stemness

Posted in Stem Cells | Comments Off on Stem cells age-discriminate organelles to maintain stemness

Age-discrimination during cell division maintains the 'stem' in stem cells

Posted: April 2, 2015 at 3:53 pm

CAMBRIDGE, Mass. (April 2, 2015) - A team of Whitehead Institute scientists has discovered that during division, stem cells distinguish between old and young mitochondria and allocate them disproportionately between daughter cells. As a result, the daughter cell destined to remain a stem cell receives predominantly young mitochondria, while the cell meant to differentiate into another cell type carries with it a higher compliment of the aged organelles.

This asymmetric apportioning of cellular contents may represent a mechanism through which stem cells prevent the accumulation of damage in their lineage over time.

"There is a fitness advantage to renewing your mitochondria," says Whitehead Member David Sabatini, whose lab reports on the phenomenon online this week in the journal Science. "Stem cells know this and have figured out a way to discard their older components."

Among the hallmarks of stem cells is so-called asymmetric cell division. Unlike their ordinary cellular counterparts, which divide symmetrically to create two cells with identical fates, stem cell division can produce one daughter cell that will remain a stem cell and another bound for further differentiation into another cell type. Scientists have observed that non-mammalian organisms are able to apportion damaged components asymmetrically during cell division, but it was unclear whether mammalian stem cells could behave similarly.

To answer this question, scientists in Sabatini's lab studied stem-like cells (SLCs) from cultures of immortalized human mammary epithelial cells. These SLCs were chosen because they express genes associated with the stem-cell state (referred to as stemness), are able to form structures known as mammospheres in culture. To track the destinations of subcellular components during cell division, the researchers, led by former postdoctoral scientist Pekka Katajisto, tagged the components--including lysosomes, mitochondria, Golgi apparatus, ribosomes, and chromatin--with a fluorescent protein that glows when hit by a pulse of ultraviolet light.

By tracing the movements of the glowing organelles, the researchers were able to demonstrate that while the normal epithelial cells distributed all of the tagged components symmetrically to daughter cells, the SLCs localized their older mitochondria distinctly and passed on the lion's share of them to the daughter cells headed for differentiation. The researchers ultimately found that the number of older mitochondria in those cells was roughly six times that in daughter cells whose fate was to remain as stem cells.

In a series of additional experiments, the scientists found that cells that inherited fewer old mitochondria during asymmetric division formed three times the number of mammospheres per 1000 cells than the daughter cells inheriting a greater proportion old mitochondria. This was an indication that cells with fewer of these old organelles were, by the mammosphere-forming criterion, more stem-like. Further, they discovered that chemically disrupting the cells' inherent mitochondrial quality-control mechanisms prevented asymmetric apportioning of young and old mitochondria and caused the loss of stem-like characteristics. Taken together, these results indicate that this disproportionate allocation of aged mitochondria during stem cell division is essential for maintaining stemness in the next generation.

"While we do not know how stem cells recognize the age of their mitochondria, forced symmetric apportioning of aged mitochondria resulted in loss of stemness in all of the daughter cells," says Katajisto, the first author of the Science paper who now runs a lab at the Institute of Biotechnology at University of Helsinki. "This suggests that the age-selective apportioning of old and potentially damaged organelles may be a way to fight stem cell exhaustion and aging."

Katajisto is now exploring whether this phenomenon occurs in other cell types beyond the human mammary epithelial SLCs examined here as well as in in vivo studies.

###

Read more here:
Age-discrimination during cell division maintains the 'stem' in stem cells

Posted in Stem Cells | Comments Off on Age-discrimination during cell division maintains the 'stem' in stem cells

Stem cell procedures for paralysis patients

Posted: April 2, 2015 at 3:53 pm

According to the Christopher and Dana Reeve Foundation, nearly one in 50 people are living with paralysis.

Until now, there wasn't much hope.

But, a new study involving stem cells has doctors and patients excited.

Two years ago, Brenda Guerra's life changed forever.

"They told me that I went into a ditch and was ejected out of the vehicle," says Brenda.

The accident left the 26-year-old paralyzed from the waist down and confined to a wheelchair.

"I don't feel any of my lower body at all," says Brenda.

Brenda has traveled from Kansas to UC San Diego to be the first patient to participate in a ground-breaking safety trial, testing stem cells for paralysis.

"We are directly injecting the stem cells into the spine," says Dr. Joseph Ciacci, a neurosurgeon at UC San Diego.

The stem cells come from fetal spinal cords. The idea is when they're transplanted they will develop into new neurons and bridge the gap created by the injury by replacing severed or lost nerve connections. They did that in animals and doctors are hoping for similar results in humans. The ultimate goal: to help people like Brenda walk again.

View post:
Stem cell procedures for paralysis patients

Posted in Stem Cells | Comments Off on Stem cell procedures for paralysis patients

Researchers produce iPSC model to better understand genetic lung/liver disease

Posted: April 2, 2015 at 3:51 pm

(Boston)--Using patient-derived stem cells known as induced pluripotent stem cells (iPSC) to study the genetic lung/liver disease called alpha-1 antitrypsin (AAT) deficiency, researchers have for the first time created a disease signature that may help explain how abnormal protein leads to liver disease.

The study, which appears in Stem Cell Reports, also found that liver cells derived from AAT deficient iPSCs are more sensitive to drugs that cause liver toxicity than liver cells derived from normal iPSCs. This finding may ultimately lead to new treatments for the condition.

IPSC's are derived from the donated skin or blood cells of adults and, with the reactivation of four genes, are reprogrammed back to an embryonic stem cell-like state. Like embryonic stem cells, iPSC can be differentiated toward any cell type in the body, but they do not require the use of embryos. Alpha-1 antitrypsin deficiency is a common genetic cause of both liver and lung disease affecting an estimated 3.4 million people worldwide.

Researchers from the Center for Regenerative Medicine (CReM) at Boston University and Boston Medical Center (BMC) worked for several years in collaboration with Dr. Paul Gadue and his group from Children's Hospital of Philadelphia to create iPSC from patients with and without AAT deficiency. They then exposed these cells to certain growth factors in-vitro to cause them to turn into liver-like cells, in a process that mimics embryonic development. Then the researchers studied these "iPSC-hepatic cells" and found the diseased cells secrete AAT protein more slowly than normal cells. This finding demonstrated that the iPSC model recapitulates a critical aspect of the disease as it occurs in patients. AAT deficiency is caused by a mutation of a single DNA base. Correcting this single base back to the normal sequence fixed the abnormal secretion.

"We found that these corrected cells had a normal secretion kinetic when compared with their diseased, parental cells that are otherwise genetically identical except for this single DNA base," explained lead author Andrew A. Wilson, MD, assistant professor of medicine at Boston University School of Medicine and Director of the Alpha-1 Center at Bu and BMC.

They also found the diseased (AAT deficient) iPSC-liver cells were more sensitive to certain drugs (experience increased toxicity) than those from normal individuals. "This is important because it suggests that the livers of actual patients with this disease might be more sensitive in the same way," said Wilson, who is also a physician in pulmonary, critical care and allergy medicine at BMC.

According to Wilson, while some patients are often advised by their physicians to avoid these types of drugs, these recommendations are not based on solid scientific evidence. "This approach might now be used to generate that sort of evidence to guide clinical decisions," he added.

The researchers believe that studies using patient-derived stem cells will allow them to better understand how patients with AAT deficiency develop liver disease. "We hope that the insights we gain from these studies will result in the discovery of new potential treatments for affected patients in the near future," said Wilson.

###

Funding was provided by an ARRA stimulus grant (1RC2HL101535-01) awarded by the National Institutes of Health (NIH) to Boston University School of Medicine, Boston Medical Center and the Children's Hospital of Philadelphia. Additional funding was provided by K08 HL103771, FAMRI 062572_YCSA, an Alpha-1 Foundation Research Grant and a Boston University Department of Medicine Career Investment Award. Additional grants from NIH 1R01HL095993 and 1R01HL108678 and an ARC award from the Evans Center for Interdisciplinary Research at Boston University supported this work.

Read the original here:
Researchers produce iPSC model to better understand genetic lung/liver disease

Posted in Genetic medicine | Comments Off on Researchers produce iPSC model to better understand genetic lung/liver disease

iPSC model helps to better understand genetic lung/liver disease

Posted: April 2, 2015 at 3:51 pm

Using patient-derived stem cells known as induced pluripotent stem cells (iPSC) to study the genetic lung/liver disease called alpha-1 antitrypsin (AAT) deficiency, researchers have for the first time created a disease signature that may help explain how abnormal protein leads to liver disease.

The study, which appears in Stem Cell Reports, also found that liver cells derived from AAT deficient iPSCs are more sensitive to drugs that cause liver toxicity than liver cells derived from normal iPSCs. This finding may ultimately lead to new treatments for the condition.

IPSC's are derived from the donated skin or blood cells of adults and, with the reactivation of four genes, are reprogrammed back to an embryonic stem cell-like state. Like embryonic stem cells, iPSC can be differentiated toward any cell type in the body, but they do not require the use of embryos. Alpha-1 antitrypsin deficiency is a common genetic cause of both liver and lung disease affecting an estimated 3.4 million people worldwide.

Researchers from the Center for Regenerative Medicine (CReM) at Boston University and Boston Medical Center (BMC) worked for several years in collaboration with Dr. Paul Gadue and his group from Children's Hospital of Philadelphia to create iPSC from patients with and without AAT deficiency. They then exposed these cells to certain growth factors in-vitro to cause them to turn into liver-like cells, in a process that mimics embryonic development. Then the researchers studied these "iPSC-hepatic cells" and found the diseased cells secrete AAT protein more slowly than normal cells. This finding demonstrated that the iPSC model recapitulates a critical aspect of the disease as it occurs in patients. AAT deficiency is caused by a mutation of a single DNA base. Correcting this single base back to the normal sequence fixed the abnormal secretion.

"We found that these corrected cells had a normal secretion kinetic when compared with their diseased, parental cells that are otherwise genetically identical except for this single DNA base," explained lead author Andrew A. Wilson, MD, assistant professor of medicine at Boston University School of Medicine and Director of the Alpha-1 Center at Bu and BMC.

They also found the diseased (AAT deficient) iPSC-liver cells were more sensitive to certain drugs (experience increased toxicity) than those from normal individuals. "This is important because it suggests that the livers of actual patients with this disease might be more sensitive in the same way," said Wilson, who is also a physician in pulmonary, critical care and allergy medicine at BMC.

According to Wilson, while some patients are often advised by their physicians to avoid these types of drugs, these recommendations are not based on solid scientific evidence. "This approach might now be used to generate that sort of evidence to guide clinical decisions," he added.

The researchers believe that studies using patient-derived stem cells will allow them to better understand how patients with AAT deficiency develop liver disease. "We hope that the insights we gain from these studies will result in the discovery of new potential treatments for affected patients in the near future," said Wilson.

Story Source:

The above story is based on materials provided by Boston University Medical Center. Note: Materials may be edited for content and length.

Original post:
iPSC model helps to better understand genetic lung/liver disease

Posted in Genetic medicine | Comments Off on iPSC model helps to better understand genetic lung/liver disease

'Open' stem cell chromosomes reveal new possibilities for diabetes

Posted: April 2, 2015 at 3:47 pm

Stem cells hold great promise for treating a number of diseases, in part because they have the unique ability to differentiate, specializing into any one of the hundreds of cell types that comprise the human body. Harnessing this potential, though, is difficult. In some cases, it takes up to seven carefully orchestrated steps of adding certain growth factors at specific times to coax stem cells into the desired cell type. Even then, cells of the intestine, liver and pancreas are notoriously difficult to produce from stem cells. Writing in Cell Stem Cell April 2, researchers at University of California, San Diego School of Medicine have discovered why.

It turns out that the chromosomes in laboratory stem cells open slowly over time, in the same sequence that occurs during embryonic development. It isn't until certain chromosomal regions have acquired the "open" state that they are able to respond to added growth factors and become liver or pancreatic cells. This new understanding, say researchers, will help spur advancements in stem cell research and the development of new cell therapies for diseases of the liver and pancreas, such as type 1 diabetes.

"Our ability to generate liver and pancreatic cells from stem cells has fallen behind the advances we've made for other cell types," said Maike Sander, MD, professor of pediatrics and cellular and molecular medicine and director of the Pediatric Diabetes Research Center at UC San Diego. "So we haven't yet been able to do things like test new drugs on stem cell-derived liver and pancreatic cells. What we have learned is that if we want to make specific cells from stem cells, we need ways to predict how those cells and their chromosomes will respond to the growth factors."

Sander led the study, together with co-senior author Bing Ren, PhD, professor of cellular and molecular medicine at UC San Diego and Ludwig Cancer Research member.

Chromosomes are the structures formed by tightly wound and packed DNA. Humans have 46 chromosomes -- 23 inherited from each parent. Sander, Ren and their teams first made maps of chromosomal modifications over time, as embryonic stem cells differentiated through several different developmental intermediates on their way to becoming pancreatic and liver cells. Then, in analyzing these maps, they discovered links between the accessibility (openness) of certain regions of the chromosome and what they call developmental competence -- the ability of the cell to respond to triggers like added growth factors.

"We're also finding that these chromosomal regions that need to open before a stem cell can fully differentiate are linked to regions where there are variations in certain disease states," Sander says.

In other words, if a person were to inherit a genetic variation in one of these chromosomal regions and his or her chromosome didn't open up at exactly the right time, he or she could hypothetically be more susceptible to a disease affecting that cell type. Sander's team is now working to further investigate what role, if any, these chromosomal regions and their variations play in diabetes.

Story Source:

The above story is based on materials provided by University of California - San Diego. The original article was written by Heather Buschman, PhD. Note: Materials may be edited for content and length.

Read this article:
'Open' stem cell chromosomes reveal new possibilities for diabetes

Posted in Cell Medicine | Comments Off on 'Open' stem cell chromosomes reveal new possibilities for diabetes

Orthopedic Stem Cell Therapy for Arthritic Joint Pain – Video

Posted: April 2, 2015 at 3:46 pm


Orthopedic Stem Cell Therapy for Arthritic Joint Pain
Dr. Sergio Viroslav, board certified orthopedic surgeon and joint replacement specialist with The San Antonio Orthopaedic Group, appeared on Great Day SA on March 30th, 2015 to discuss the...

By: The San Antonio Orthopaedic Group

Read the original post:
Orthopedic Stem Cell Therapy for Arthritic Joint Pain - Video

Posted in Stem Cell Therapy | Comments Off on Orthopedic Stem Cell Therapy for Arthritic Joint Pain – Video

Can PRP and Stem Cell Therapy Help You? | Orlando Orthopaedic Center – Video

Posted: April 2, 2015 at 3:46 pm


Can PRP and Stem Cell Therapy Help You? | Orlando Orthopaedic Center
How can PRP and stem cell therapy help you heal? Orlando Orthopaedic Center #39;s Dr. Matthew R. Willey explains. For more visit http://www.OrlandoOrtho.com.

By: OrlandoOrtho

See the rest here:
Can PRP and Stem Cell Therapy Help You? | Orlando Orthopaedic Center - Video

Posted in Stem Cell Therapy | Comments Off on Can PRP and Stem Cell Therapy Help You? | Orlando Orthopaedic Center – Video

Page 1,811«..1020..1,8101,8111,8121,813..1,8201,830..»